Key result
Irisin shows conflicting therapeutic potential for hypertension and metabolic disorders despite compensatory metabolic links.
Why the study?
The mechanisms of action of irisin and its associations with metabolic diseases including obesity, type 2 diabetes, lipid disorders, and hypertension remain largely unexplained.
Does not support irisin modulation in hypertension care; leaves open its therapeutic role pending consistent trials.
Irisin is a myokine secreted by skeletal muscles. It has been proposed to drive the brown-fat-like conversion of the white adipose tissue. By enhancing energy expenditure, irisin may affect systemic metabolism and be associated with insulin resistance; however, the mechanism(s) of action still remain largely unexplained. The discovery of irisin can contribute to the exploration of the novel and effective therapeutic targets or therapeutic strategies of metabolic diseases or metabolism-associated health issues. In this review, based on the recent literature (from 2013 to 2015 inclusive), we will systematically discuss the associations of irisin with obesity, type 2 diabetes, lipid disorders, and hypertension. We also introduce unanswered questions for future research.
No takes yet. Share an insight, caveat, or question.
Taszarek et al. (2016) conducted a review in Hypertension, metabolic diseases, obesity, type 2 diabetes, and lipid disorders. Irisin was evaluated. While increased circulating irisin may reflect a compensatory response to impaired insulin sensitivity, its therapeutic potential for hypertension and metabolic disorders remains challenged by contradictory findings.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: